T 1616/09 (Combination therapy with anti-neoplastic agent and DNA methylation … of 27.8.2014

European Case Law Identifier: ECLI:EP:BA:2014:T161609.20140827
Date of decision: 27 August 2014
Case number: T 1616/09
Application number: 02717415.0
IPC class: A61K 45/00
A61P 35/00
Language of proceedings: EN
Distribution: C
Download and more information:
Decision text in EN (PDF, 307 KB)
Documentation of the appeal procedure can be found in the Register
Bibliographic information is available in: EN
Versions: Unpublished
Title of application: RESTORATION OF CANCER-SUPPRESSING FUNCTIONS TO NEOPLASTIC CELLS THROUGH DNA HYPOMETHYLATION
Applicant name: SuperGen, Inc.
Opponent name: -
Board: 3.3.02
Headnote: -
Relevant legal provisions:
European Patent Convention Art 83
European Patent Convention R 42(1)(e)
European Patent Convention Art 111(1)
Keywords: Sufficiency of disclosure - (yes)
Remittal to the department of first instance (yes)
Catchwords:

For the purposes of Article 83 EPC, the level of disclosure in the application which is required for claims directed to pharmaceutical compositions or kits is not the same as that which is required for medical-use claims. For claims directed to pharmaceutical compositions or kits it is in principle sufficient that the application provides information which allows the skilled person to produce the composition or kit, and that there are no substantiated doubts that it could indeed be used in therapy. For second-medical-use claims on the other hand it is required not only that the composition itself is disclosed in an enabling way but also that its suitability for the claimed treatment is plausibly disclosed in the application (Reasons 6).

In the case of a claim directed to a pharmaceutical composition comprising two classes of compounds which have both already been used in therapy in the prior art, there is a priori no reason to doubt that such a pharmaceutical composition can be produced; no specific functional effect has to be demonstrated (Reasons 6.1.1 and 6.1.2).

In the case of second-medical-use claims, if the claimed therapeutic effect was already known to the skilled person at the priority date, it is not necessary to demonstrate it in the application (Reasons 6.2.2).

Cited decisions:
T 0609/02
Citing decisions:
T 1602/10
T 1823/11
T 0872/13
T 2571/18

7 references found.

Click X to load a reference inside the current page, click on the title to open in a new page.

EPC Articles

EPC Implementing Rules

Case Law Book: II Conditions to be met by an Application

General Case Law